Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Alan L Epstein, MD, PhD

    TitleProfessor of Pathology
    SchoolKeck School of Medicine of USC
    DepartmentPathology
    AddressHMR 205
    Health Sciences Campus
    Los Angeles California 90089-9092
    Phone+1 323 442 1172
    Emailaepstein@usc.edu
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse Required Scholarly Project Mentor

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kumar P, Alharshawi K, Bhattacharya P, Marinelarena A, Haddad C, Sun Z, Chiba S, Epstein A, Prabhakar BS. Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Sci Rep. 2017 Jan 03; 7:39751. PMID: 28045060.
        View in: PubMed
      2. Smith A, Manoli H, Jaw S, Frutoz K, Epstein A, Khawli LA, Theil FP. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res. 2016; 2016:2342187. PMID: 27579329.
        View in: PubMed
      3. Haddad CS, Bhattacharya P, Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Elshabrawy HA, Epstein A, Prabhakar BS. Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice. Autoimmunity. 2016 Aug; 49(5):298-311. PMID: 27245356.
        View in: PubMed
      4. Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP, Brody GS, Epstein A. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2016 Jul; 36(7):773-81. PMID: 26979456.
        View in: PubMed
      5. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein A. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. PMID: 26960932.
        View in: PubMed
      6. Andersen BM, Xia J, Epstein A, Ohlfest JR, Chen W, Blazar BR, Pennell CA, Olin MR. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer. 2016; 4:11. PMID: 26885373.
        View in: PubMed
      7. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein A. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. PMID: 26756227.
        View in: PubMed
      8. Jang JK, Chretin J, Bruyette D, Hu P, Epstein A. Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies. J Cancer Sci Ther. 2015; 7(6):167-174. PMID: 26635918.
        View in: PubMed
      9. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein A. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. PMID: 25490535.
        View in: PubMed
      10. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein A. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 1; 20(23):6034-44. PMID: 25294906.
        View in: PubMed
      11. Bryan RA, Jiang Z, Jandl T, Strauss J, Koba W, Onyedika C, Morgenstern A, Bruchertseifer F, Epstein A, Dadachova E. Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. PMID: 25156106.
        View in: PubMed
      12. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein A. BRAF(V600E) in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518.
        View in: PubMed
      13. Aluri SR, Shi P, Gustafson JA, Wang W, Lin YA, Cui H, Liu S, Conti PS, Li Z, Hu P, Epstein A, Mackay JA. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014 Mar 25; 8(3):2064-76. PMID: 24484356.
        View in: PubMed
      14. Andoh T, Fujimoto T, Sudo T, Suzuki M, Sakurai Y, Sakuma T, Moritake H, Sugimoto T, Takeuchi T, Sonobe H, Epstein A, Fukumori Y, Ono K, Ichikawa H. Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model. Appl Radiat Isot. 2014 Jun; 88:59-63. PMID: 24389062.
        View in: PubMed
      15. Murphy KA, Erickson JR, Johnson CS, Seiler CE, Bedi J, Hu P, Pluhar GE, Epstein A, Ohlfest JR. CD8+ T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma. J Immunol. 2014 Jan 1; 192(1):224-33. PMID: 24293627.
        View in: PubMed
      16. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein A. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. PMID: 24145359.
        View in: PubMed
      17. Jang JK, Khawli LA, Park R, Wu BW, Li Z, Canter D, Conti PS, Epstein A. Cytoreductive Chemotherapy Improves the Biodistribution of Antibodies Directed against Tumor Necrosis in Murine Solid Tumor Models. Mol Cancer Ther. 2013 Dec; 12(12):2827-36. PMID: 24130055.
        View in: PubMed
      18. Ephrem A, Epstein A, Stephens GL, Thornton AM, Glass D, Shevach EM. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol. 2013 Sep; 43(9):2421-9. PMID: 23722868.
        View in: PubMed
      19. Russell SM, Lechner MG, Mokashi A, Megiel C, Jang JK, Taylor CR, Looijenga LH, French CA, Epstein A. Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology. 2013 Feb; 81(2):464.e1-9. PMID: 23374840.
        View in: PubMed
      20. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein A. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. PMID: 23279945.
        View in: PubMed
      21. Nadelson J, Epstein A. A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome. Case Rep Gastrointest Med. 2012; 2012:164305. PMID: 23213581.
        View in: PubMed
      22. Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein A. Survival Signals and Targets for Therapy in Breast Implant-Associated ALK- Anaplastic Large Cell Lymphoma. Clin Cancer Res. 2012 Sep 1; 18(17):4549-59. PMID: 22791880.
        View in: PubMed
      23. Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein A, Ohlfest JR. An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas. Clin Cancer Res. 2012 Sep 1; 18(17):4657-68. PMID: 22781551.
        View in: PubMed
      24. Niedojadlo J, Mikulski Z, Delenko K, Szmidt-Jaworska A, Smolinski DJ, Epstein A. The perichromatin region of the plant cell nucleus is the area with the strongest co-localisation of snRNA and SR proteins. Planta. 2012 Aug; 236(2):715-26. PMID: 22526497.
        View in: PubMed
      25. Epstein A. Unique approach for B lymphoma therapy. Blood. 2012 Apr 19; 119(16):3647-8. PMID: 22517869.
        View in: PubMed
      26. Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Epstein A, Farghadani H, Kruse CA, Jadus MR, Chen TC, Schijns VE. Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin Cell Immunol. 2012; Suppl 5:004. PMID: 24955288.
        View in: PubMed
      27. Lechner MG, Russell SM, Bass RS, Epstein A. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011 Nov; 3(11):1317-40. PMID: 22053884.
        View in: PubMed
      28. Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein A. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011 Sep; 47(9):810-7. PMID: 21719345.
        View in: PubMed
      29. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein A. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011; 9:90. PMID: 21658270.
        View in: PubMed
      30. Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Sonobe H, Epstein A, Akisue T, Kirihata M, Kurosaka M, Fukumori Y, Ichikawa H. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot. 2011 Dec; 69(12):1713-6. PMID: 21354804.
        View in: PubMed
      31. Lechner MG, Epstein A. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011 Apr 1; 17(7):1645-8. PMID: 21288925.
        View in: PubMed
      32. Cohen JV, Capell BC, Kinniry PA, Epstein A. Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol. 2011 Feb; 38(2):398-9. PMID: 21285183.
        View in: PubMed
      33. Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, Epstein A. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011 Apr 1; 117(7):1478-89. PMID: 21425149.
        View in: PubMed
      34. Pardee AD, McCurry D, Alber S, Hu P, Epstein A, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 2010 Nov 15; 70(22):9041-52. PMID: 21045144.
        View in: PubMed
      35. Lechner MG, Liebertz DJ, Epstein A. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010 Aug 15; 185(4):2273-84. PMID: 20644162.
        View in: PubMed
      36. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein A. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010; 2:5. PMID: 20175927.
        View in: PubMed
      37. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol. 2009 May 1; 182(9):5430-8. PMID: 19380790.
        View in: PubMed
      38. Hamburger MI, Hamburger FH, Bergman JM, Epstein A, Brown A. Influence of an educational seminar on use of disease activity measurements by rheumatologists in treatment of rheumatoid arthritis. J Rheumatol. 2009 Mar; 36(3):532-8. PMID: 19208595.
        View in: PubMed
      39. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein A. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. PMID: 18317364.
        View in: PubMed
      40. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein A. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. PMID: 18223234.
        View in: PubMed
      41. Wang H, Cao C, Li B, Chen S, Yin J, Shi J, Ye D, Tao Q, Hu P, Epstein A, Ju D. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008 May; 57(5):677-84. PMID: 17934732.
        View in: PubMed
      42. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein A. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 1; 13(13):4016-25. PMID: 17606736.
        View in: PubMed
      43. Arias RS, Flanagan ML, Miller KD, Nien YC, Hu P, Gray D, Khawli LA, Epstein A. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. PMID: 17600493.
        View in: PubMed
      44. Zhang N, Khawli LA, Hu P, Epstein A. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. PMID: 17651040.
        View in: PubMed
      45. Tobin E, Denardo G, Zhang N, Epstein A, Liu C, Denardo S. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leuk Lymphoma. 2007 May; 48(5):944-56. PMID: 17487739.
        View in: PubMed
      46. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein A. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 1; 13(9):2758-67. PMID: 17460060.
        View in: PubMed
      47. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein A. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. PMID: 18605076.
        View in: PubMed
      48. Liu A, Hu P, Khawli LA, Epstein A. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. PMID: 16799338.
        View in: PubMed
      49. Flanagan ML, Khawli LA, Hu P, Epstein A. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. PMID: 16699370.
        View in: PubMed
      50. Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, Chen S, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein A. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. PMID: 16480326.
        View in: PubMed
      51. Liu A, Hu P, Khawli LA, Epstein A. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 1; 11(23):8492-502. PMID: 16322313.
        View in: PubMed
      52. Zhang N, Khawli LA, Hu P, Epstein A. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. PMID: 16115941.
        View in: PubMed
      53. Khawli LA, Hu P, Epstein A. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. PMID: 15837764.
        View in: PubMed
      54. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein A, Ju DW. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005 Mar 1; 23(7):1538-47. PMID: 15735129.
        View in: PubMed
      55. Li J, Hu P, Khawli LA, Yun A, Epstein A. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. PMID: 15000842.
        View in: PubMed
      56. Li J, Hu P, Khawli LA, Epstein A. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 1; 63(23):8384-92. PMID: 14679000.
        View in: PubMed
      57. Khawli LA, Alauddin MM, Hu P, Epstein A. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. PMID: 14969605.
        View in: PubMed
      58. Ottonello L, Epstein A, Mancini M, Dapino P, Dallegri F. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. J Leukoc Biol. 2004 Jan; 75(1):99-105. PMID: 14525961.
        View in: PubMed
      59. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein A. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. PMID: 12941833.
        View in: PubMed
      60. Mizokami MM, Hu P, Khawli LA, Li J, Epstein A. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. PMID: 14511565.
        View in: PubMed
      61. Li J, Hu P, Khawli LA, Epstein A. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. PMID: 12843794.
        View in: PubMed
      62. Biela BH, Khawli LA, Hu P, Epstein A. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. PMID: 12954121.
        View in: PubMed
      63. Epstein A, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. PMID: 12759392.
        View in: PubMed
      64. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein A. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. PMID: 12609842.
        View in: PubMed
      65. Khawli LA, Biela B, Hu P, Epstein A. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. PMID: 12713684.
        View in: PubMed
      66. Sharifi J, Khawli LA, Hu P, Li J, Epstein A. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. PMID: 12573106.
        View in: PubMed
      67. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein A. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. PMID: 12396700.
        View in: PubMed
      68. Moritake H, Sugimoto T, Asada Y, Yoshida MA, Maehara Y, Epstein A, Kuroda H. Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet Cytogenet. 2002 May; 135(1):48-56. PMID: 12072203.
        View in: PubMed
      69. Khawli LA, Biela BH, Hu P, Epstein A. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. PMID: 11991812.
        View in: PubMed